1. Home
  2. STAA vs FTRE Comparison

STAA vs FTRE Comparison

Compare STAA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$23.72

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$19.22

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAA
FTRE
Founded
1982
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
STAA
FTRE
Price
$23.72
$19.22
Analyst Decision
Buy
Buy
Analyst Count
9
9
Target Price
$22.81
$14.06
AVG Volume (30 Days)
958.8K
1.4M
Earning Date
05-12-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$239,442,000.00
$2,723,400,000.00
Revenue This Year
$30.82
N/A
Revenue Next Year
$8.41
$3.09
P/E Ratio
$243.60
N/A
Revenue Growth
N/A
1.00
52 Week Low
$15.59
$5.82
52 Week High
$35.87
$21.39

Technical Indicators

Market Signals
Indicator
STAA
FTRE
Relative Strength Index (RSI) 40.20 58.79
Support Level $23.71 $15.69
Resistance Level $24.26 N/A
Average True Range (ATR) 1.52 1.07
MACD -0.04 -0.01
Stochastic Oscillator 34.23 46.27

Price Performance

Historical Comparison
STAA
FTRE

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Share on Social Networks: